Progentec Diagnostics
- Company typePrivate
- Founded2015
- HeadquartersOklahoma City, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Progentec Diagnostics firmographics
Firmographics- Name
- Progentec Diagnostics
- Legal name
- Progentec Diagnostics, Inc.
- Website
- https://progentec.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Progentec Diagnostics industry classification
Industry- Product category
- Autoimmune Disease Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
- akta.pro secondary industries
- Proteomics & Biomarker Analytical Testing (HLAGADAG), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Autoimmune & Allergy Diagnostics (HLAAALAK), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Proteomics & Mass Spectrometry Services (HLAGANAB)
Keywords
Where Progentec Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Oklahoma City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Progentec Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Laboratory Diagnostic Testing: Revenue from proprietary blood biomarker tests (aiSLE DX FRI and aiSLE DX DAI) sold to rheumatologists and healthcare systems. Tests are billed via PLA codes (0446U, 0447U) at $840.65 Medicare rate when covered. Distribution through Mayo Clinic Laboratories and direct ordering.
- Digital Health Platform Services: aiSLE MGMT platform combining laboratory tests with digital tools, health coaching, and remote monitoring services for comprehensive lupus management.
- Clinical Research Services: Decentralized clinical study technologies and study management services provided to pharmaceutical companies and research institutions including GSK partnership.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Medicare-covered testing at $840.65 per test |
| Subscription | Monthly | aiSLE MGMT with aiSLE Access For All financial support |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels8 records
Progentec Diagnostics product offering
Product offeringCore offering
Progentec Diagnostics develops and commercializes proprietary blood-based proteomics biomarker tests (the aiSLE DX Flare Risk Index and Disease Activity Index) that analyze immune mediators to predict lupus flares up to 12 weeks in advance and objectively measure current SLE disease activity. The company complements these laboratory tests with a digital health ecosystem—the aiSLE MGMT platform, AutoimmuneCorner mobile app with wearable integration, and LupusCorner Research decentralized clinical study platform—offered to rheumatologists, healthcare systems, and pharmaceutical sponsors through Mayo Clinic Laboratories and direct ordering.
Product overview
Progentec Diagnostics operates as a platform-plus-modules company offering both proprietary laboratory biomarker tests and a digital health ecosystem for autoimmune disease management. The core aiSLE DX family of tests includes the Flare Risk Index (FRI) and Disease Activity Index (DAI), both commercially available blood tests analyzing immune mediators to predict and measure lupus disease activity. These tests are delivered through Mayo Clinic Laboratories and directly via Progentec's CLIA-certified lab. The aiSLE MGMT platform integrates these laboratory results with the AutoimmuneCorner mobile app (featuring health coaching and Withings smartwatch integration), LupusCorner patient engagement tools, and LupusCorner Research for decentralized clinical studies. The pipeline includes aiSLE DX Classification for lupus diagnosis, and the aiMS DX suite of tests for multiple sclerosis management including relapse prediction, disease activity measurement, and interferon treatment response monitoring.
Differentiator
Problem solved
Functional benefit
Brands
- aiSLE MGMT: A lupus management platform combining aiSLE DX laboratory tests with AutoimmuneCorner mobile app and health coaching for proactive lupus care.
- LupusCorner
- AutoimmuneCorner
- aiSLE DX
- LupusCorner Research
Products and services
- aiSLE DX Flare Risk Index (FRI) A proprietary blood-based proteomics test powered by LiquidFlareRisk technology that analyzes 11 immune mediators (cytokines, chemokines, and soluble receptors) to predict the likelihood of an SLE disease flare within 12 weeks, with an odds ratio approaching 5.0 (p=0.0015). Validated in European American, African American, and Native American cohorts; ordered by rheumatologists and reimbursed under PLA code 0446U at $840.65. Distributed through Mayo Clinic Laboratories and direct practice ordering.
- aiSLE DX Disease Activity Index (DAI) A proprietary blood-based biomarker test powered by LiquidDiseaseActivity technology that provides an objective measure of current SLE disease activity, distinguishing active versus low/quiescent disease and calibrated against hybrid SLEDAI scoring. Reimbursed under PLA code 0447U at $840.65; ordered by rheumatologists through Mayo Clinic Laboratories or directly from Progentec.
- aiSLE MGMT Care Platform A comprehensive lupus management platform combining aiSLE DX laboratory tests with the AutoimmuneCorner mobile app (symptom/flare tracking, Withings Steel HR wearable integration, validated PROs) and health coaching services to deliver proactive lupus care. Offered as a subscription with tiered patient co-pays under the aiSLE Access For All program ($0, $26, or $50 based on household income).
- LupusCorner Research
Quantifiable outcome
- Patients with positive aiSLE DX Flare Risk Index score are almost 5 times more likely to flare (OR approaches 5.0, p=0.0015)
- +2 more outcomes
Companies that use Progentec Diagnostics
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Progentec Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability11 records
Feature7 records
Progentec Diagnostics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship, core and minor.
- Mayo Clinic LaboratoriesflagshipStrategic collaboration to bring Progentec's proprietary biomarker blood tests for autoimmune disease management to market. Mayo Clinic Laboratories serves as the exclusive reference laboratory distributor for aiSLE DX Flare Risk Index and aiSLE DX Disease Activity Index tests, available to Mayo's network of 3,400+ healthcare organizations globally. Tests became available April 25, 2024.
- GSKcoreResearch collaboration to assess proteomics and digital health tools for lupus (SLE) care. Includes the PROACTIVE study (launched March 2023) for early lupus screening and identification of individuals at risk. Joint development of lupus diagnostic and monitoring solutions.
- Stanford UniversitycoreLicensing agreement for multiple sclerosis technologies developed at Stanford University. Covers laboratory technologies related to MS diagnosis and monitoring.
- Karate HealthcoreMerger with Karate Health, maker of digital technologies for chronic health conditions, to create comprehensive autoimmune disease management platform combining laboratory testing and digital tools.
- Oklahoma Medical Research Foundation (OMRF)coreCollaboration to commercialize autoimmune diagnostic technologies developed at OMRF. Includes licensing of lupus biomarker technology from Dr. Judith James's research. OMRF scientists (Dr. Melissa Munroe, Dr. Judith James) involved in product development.
- BendcareminorSupports aiSLE DX Flare Risk Index testing access for patients with lupus (SLE), helping expand patient access to the test.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Progentec Diagnostics competitors and assessment
Company assessmentDirect peers
- Exagen Inc. Exagen develops AVISE CTD and AVISE SLE diagnostic tests for autoimmune diseases including lupus — the closest direct competitor to Progentec's aiSLE DX franchise. Both companies serve rheumatologists with blood-based biomarker tests for SLE diagnosis, monitoring, and management.
- Inova Diagnostics (Werfen): Inova Diagnostics, part of Werfen, is a global leader in autoimmune disease diagnostics with a broad menu of specialty immunology assays and biomarker tests. Directly competes with Progentec in autoimmune serology and proteomics-based testing.
- Sengenics: Sengenics provides proteomics-based biomarker discovery and autoimmune diagnostics using high-content protein array technology. Directly comparable to Progentec's proteomics + autoimmune disease focus.
- Euroimmun (PerkinElmer): Euroimmun, part of Revvity/PerkinElmer, is a leading autoimmune diagnostics company offering a comprehensive portfolio of specialty immunology tests — a direct competitor in autoimmune lab testing serving rheumatology.
Broad incumbents
- Thermo Fisher Scientific: Thermo Fisher supplies the proteomics instruments (e.g., mass spectrometry, multiplex immunoassay platforms) and provides specialty lab services used in autoimmune biomarker work. A broad incumbent with overlapping capabilities but not specializing in SLE.
- Bio-Techne: Bio-Techne manufactures proteomics reagents and assay kits (including the ProteinSimple Ella microfluidic platform Progentec uses) and offers tools for cytokine/chemokine biomarker discovery — comparable as a proteomics-enabling incumbent.
- Laboratory Corporation of America (LabCorp): LabCorp is one of the largest clinical laboratory networks in the US offering autoimmune and rheumatology testing panels — a broad incumbent competitor whose reach could compete with Progentec's specialty tests if validated into routine panels.
- Quest Diagnostics: Quest Diagnostics is the largest US clinical lab company, offering specialty immunology and autoimmune test panels through its reference lab network. Comparable as a broad incumbent with overlapping capabilities.
Emerging players
- Adaptive Biotechnologies: Adaptive Biotechnologies uses immune receptor sequencing and immune profiling to develop diagnostic and monitoring tools — adjacent technology with comparable focus on immune-mediated disease biomarkers, though commercially more established.
Regional players
- Myriad Genetics: Myriad Genetics offers genetic and molecular diagnostic tests in autoimmune and rheumatology-adjacent indications. Comparable as a specialty diagnostics company operating primarily in the US with a similar profile of focused molecular tests.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Progentec Diagnostics social profiles
Digital presenceProgentec Diagnostics compliance and trust
Trust signalCompliance3 records
Progentec Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Progentec Diagnostics leadership team
Management profileNumber of profiles
Profiles11 records
Progentec Diagnostics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Progentec Diagnostics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Progentec Diagnostics
What does Progentec Diagnostics do?
Progentec Diagnostics develops and commercializes proprietary blood-based proteomics biomarker tests (the aiSLE DX Flare Risk Index and Disease Activity Index) that analyze immune mediators to predict lupus flares up to 12 weeks in advance and objectively measure current SLE disease activity. The company complements these laboratory tests with a digital health ecosystem—the aiSLE MGMT platform, AutoimmuneCorner mobile app with wearable integration, and LupusCorner Research decentralized clinical study platform—offered to rheumatologists, healthcare systems, and pharmaceutical sponsors through Mayo Clinic Laboratories and direct ordering.
Is Progentec Diagnostics a public or private company?
Progentec Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Progentec Diagnostics founded?
Progentec Diagnostics was founded in 2015. It employs 1 to 10 people.
Where is Progentec Diagnostics based?
Progentec Diagnostics is headquartered in Oklahoma City, United States, in the North America region.
How does Progentec Diagnostics make money?
Three revenue lines are on record. Laboratory Diagnostic Testing is the primary driver. The others are digital Health Platform Services and clinical Research Services.
Who are Progentec Diagnostics's main competitors?
Direct peers on record are Exagen Inc., Inova Diagnostics (Werfen), Sengenics and Euroimmun (PerkinElmer). Broad incumbents are Thermo Fisher Scientific, Bio-Techne, Laboratory Corporation of America (LabCorp) and Quest Diagnostics. Adaptive Biotechnologies is listed as an emerging player. Myriad Genetics is listed as a regional player.
Does Progentec Diagnostics have an API?
No public API is recorded for Progentec Diagnostics.
What industry is Progentec Diagnostics in?
Progentec Diagnostics's product category is Autoimmune Disease Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 621511 and its SIC code is 2835.